Contact Us     Team     News
UT Advance

Services and Capabilities

GLP studies are conducted according to the FDA's standards set in 21 CFR part 58. One of the major bottlenecks limiting successful new drug development is preclinical safety.   Inhaled drug formulations can be particularly challenging during preclinical testing due to complexities involved in drug aerosolization.   Additionally, for IND-enabling studies, the FDA requires that Good Laboratory Practices (GLP) be implemented and followed closely throughout a project.   To address these challenges, UT Advance has combined its aerosol expertise and regulatory oversight to assist in progressing inhaled drug products to the clinic.  Using highly controlled aerosol exposure systems and advanced characterization tools, our studies offer dose control for both traditional and engineered formulations.  In partnership with TherapeUTex, UT Advance can also assist with pharmacokinetic, non-GLP toxicity, and efficacy studies where a precisely controlled aerosol dose is needed.


Our goal is to aid the progression of drug products and technologies through the development process by providing services including drug formulation and delivery, in vitro and in vivo preclinical and proof-of-concept studies, histological preparation, and lab-scale formulation and production.
More about TherapeUTex

We've built the regulatory environment necessary to meet FDA requirements for drug evaluation. And, we've assembled the scientific expertise to design effective studies. Our goal is to assist researchers by providing the studies required for a successful FDA submission.
More about UT Advance

The UTech Dorm Room provides wet lab space for Austin's bioscience community.
More about UTECH Dorm Room

Comments to:
Download free PDF Reader | Download free MS Reader
Privacy Policy | Accessibility Policy
©2012 College of Pharmacy, The University of Texas at Austin
College of Pharmacy, Univ of Texas